Welcome to our dedicated page for Relief Therapeut news (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on Relief Therapeut stock.
The RLFTY news page on Stock Titan aggregates company-issued announcements and related coverage for RELIEF THERAPEUTICS Holding SA and the combined entity MindMaze Therapeutics Holding SA. These disclosures describe a transition from a rare-disease biopharmaceutical focus toward an integrated platform that combines digital neurotherapeutics with specialty biopharmaceutical assets.
News items include updates on Relief’s clinical pipeline, such as RLF‑TD011 for epidermolysis bullosa and RLF‑OD032 for phenylketonuria. Releases detail regulatory designations, clinical trial progress and bioequivalence results, providing insight into how the company advances candidates targeting rare dermatological, metabolic and respiratory conditions.
Another major theme in the RLFTY news flow is corporate transformation. The company has reported on a proposed and then completed business combination with NeuroX Group SA, which operates the MindMaze digital neurotherapeutics platform. Articles describe shareholder approvals, capital increases, and the renaming of the company to MindMaze Therapeutics Holding SA, as well as the subsequent listing of the combined entity under the ticker MMTX on the SIX Swiss Exchange.
Additional coverage highlights MindMaze Therapeutics’ activities, including its reimbursement strategy for digital neurorehabilitation, participation in national evidence-generation programs, and alignment with health technology assessment frameworks. These updates explain how the company positions its AI-enabled neurotherapeutics for deployment across clinics and home settings.
Investors and observers can use this news page to follow clinical milestones, regulatory interactions, reimbursement developments and key corporate events affecting RLFTY and the underlying Swiss-listed company. Regularly reviewing these items helps build a picture of how the combined business is evolving across neurology-focused digital therapeutics and rare-disease biopharmaceutical programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Relief Therapeutics announced positive 12-month stability data for RLF-100 ®, an investigational formulation of aviptadil acetate for inhaled and intravenous administration. Both formulations demonstrated high purity levels after one year across various temperature conditions, confirming previous findings at three and six months. In response to these results, Relief plans to amend its provisional patent application, potentially extending exclusivity until 2042, factoring in possible Hatch-Waxman extensions.
CEO Jack Weinstein emphasized the commercial potential of the stable formulation, aiming to establish RLF-100 ® as a standard treatment for respiratory failure. The FDA previously granted Orphan Drug designation for RLF-100 ® targeting pulmonary sarcoidosis.